Business Description
Citius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US17322U2078
Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 47.43 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.3 | |||||
| 3-Year EPS without NRI Growth Rate | 21.2 | |||||
| 3-Year FCF Growth Rate | 23.7 | |||||
| 3-Year Book Growth Rate | -1.9 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.28 | |||||
| 9-Day RSI | 39.22 | |||||
| 14-Day RSI | 42.56 | |||||
| 6-1 Month Momentum % | 3.07 | |||||
| 12-1 Month Momentum % | -43.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.06 | |||||
| Quick Ratio | 5.06 | |||||
| Cash Ratio | 3.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.9 | |||||
| Shareholder Yield % | 0.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -41.06 | |||||
| ROA % | -36.2 | |||||
| ROIC % | -54.12 | |||||
| ROC (Joel Greenblatt) % | -1812.3 | |||||
| ROCE % | -38.86 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.38 | |||||
| Price-to-Tangible-Book | 7.33 | |||||
| EV-to-EBIT | -2.42 | |||||
| EV-to-Forward-EBIT | -6.05 | |||||
| EV-to-EBITDA | -2.44 | |||||
| EV-to-Forward-Revenue | 0.75 | |||||
| EV-to-FCF | -3.1 | |||||
| Price-to-Net-Current-Asset-Value | 7.33 | |||||
| Price-to-Net-Cash | 14.65 | |||||
| Earnings Yield (Greenblatt) % | -41.32 | |||||
| FCF Yield % | -26.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTXR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.26 | ||
| Beta | 1.51 | ||
| Volatility % | 59.47 | ||
| 14-Day RSI | 42.56 | ||
| 14-Day ATR ($) | 0.083854 | ||
| 20-Day SMA ($) | 0.84903 | ||
| 12-1 Month Momentum % | -43.92 | ||
| 52-Week Range ($) | 0.6 - 1.56 | ||
| Shares Outstanding (Mil) | 159.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Citius Pharmaceuticals Inc Frequently Asked Questions
What is Citius Pharmaceuticals Inc(CTXR)'s stock price today?
The current price of CTXR is $0.73. The 52 week high of CTXR is $1.56 and 52 week low is $0.60.
When is next earnings date of Citius Pharmaceuticals Inc(CTXR)?
The next earnings date of Citius Pharmaceuticals Inc(CTXR) is 2024-05-10 Est..
Does Citius Pharmaceuticals Inc(CTXR) pay dividends? If so, how much?
Citius Pharmaceuticals Inc(CTXR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers